Showing 1301-1310 of 1861 results for "".
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- With New Roles for Company Vets, Crown Doubles Down on Commitment to Aestheticshttps://practicaldermatology.com/news/with-new-roles-for-industry-vets-crown-doubles-down-on-commitment-to-aesthetics/2461242/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- June 2022 Marks Scleroderma Awareness Monthhttps://practicaldermatology.com/news/june-2022-marks-scleroderma-awareness-month/2461222/June is Scleroderma Awareness Month, and "Know Scleroderma" is the National Scleroderma Foundation's theme for 2022. Throughout the month, the Foundation will post videos and photos of individuals affected by scleroderma on its
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic derma
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- Healthy-appearing Lupus Skin Predisposed to Flares, Rasheshttps://practicaldermatology.com/news/healthy-appearing-lupus-skin-predisposed-to-flares-rashes/2461181/Normal-appearing skin of lupus patients contains the same inflammatory signals that are detected when the skin develops a rash – sometimes at even higher levels, according to a study in Science Translational Medicine. “This really starts to piece the puzzle together
- Virtual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® Coming Soonhttps://practicaldermatology.com/news/virtual-skin-cancer-symposium-symposium-for-inflammatory-skin-disease-coming-soon/2461166/The 2nd Annual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® (SCS + SISD) will be held virtually June 10-12, 2022. Fifteen well-known speakers will deliver 15 hours of CME credit on topics such as BCC, SCC, melanoma, actinic keratosis, dermosc
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der